Birth Control Drugs: Learn the Terrible Truth
Why did an Austrian medical researcher receive a $7.4 million “Innovator’s Award” last month from the U.S. Government?
Because the good doctor recently discovered exactly why birth control drugs and hormone replacement drugs increase a woman’s risk of developing invasive breast cancer while a woman is using either type drug.
Austrian geneticist, Josef Penninger, finally hit the nail on the head. His new research shows that progestin (a chemical found in all contraceptive drugs and some hormone replacement drugs), activates a protein called RANKL, which actually causes breast cancer cells to multiply rapidly.
Listen to what Dr. Penninger has to say about his discovery.
“Ten years ago we formulated the hypothesis that RANKL might be involved in breast cancer and it took us a long time to develop a system to prove this idea, …I have to admit it completely surprised me just how massive the effects of the system were. Millions of women take progesterone derivatives in contraceptives and for hormonal replacement therapy.”
The new ebook, Busting Breast Cancer: Birth Control Drugs includes this breaking news, along with never-before-published government statistics on the double digit annual increase in invasive breast cancer rates among U.S. women of childbearing age.
Don’t miss Birth Control Drugs: Learn the Terrible Truth: Volume 1 of the Busting Breast Cancer: 7 Simple Steps Ebook Series, by Busting Breast Cancer’s founding director, Susan Wadia-Ells…available next week on Kindle and in early December on Nook and iPads. ——————————————————
Schramek et al. (2010), “Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer”, Nature, volume 468, number 7320:98-102.
Institute of Molecular Biotechnology, “Researchers find how HRT and the Pill can lead to breast cancer and suggest possible treatment,” IMBA Press Release, (September 29, 2010).
Innovator Award to J. Penninger for project “Novel Approaches to Breast Cancer Prevention and Inhibition of Metastases,” (contract number W81XWH-12-1-0093) through the US Department of Defense. Congressionally Directed Medical Research Program: http://cdmrp.army.mil/bcrp/ (October 2012).